Veröffentlichungen

Background: Historically, treatment for hereditary angioedema (HAE) attacks has been administered by healthcare professionals (HCPs). Patient self-adminis- tration could reduce delays between symptom onset and treatment, and attack burden. The primary objective was to assess the safety of self-administered icati- bant in patients with HAE type I or II. Secondary objectives included patient convenience and clinical efficacy of self-administration.

Methods: In this phase IIIb, open-label, multicenter study, adult patients were trained to self-administer a single 30-mg icatibant subcutaneous injection to treat their next attack. Icatibant-na€ıve patients were treated by an HCP prior to self- administration. Evaluations included adverse event (AE) reporting, a validated questionnaire for convenience, and visual analog scale for efficacy.

Results: A total of 151 patients were enrolled; 104 had an attack requiring treatment during the study, and 97 patients (19 na€ıve) were included in the self- administration cohort. Recurrence or worsening of HAE symptoms (22 of 97) was the most commonly reported AE; rescue medications including icatibant (N = 3) and C1-inhibitor concentrate (N = 6) were used in 13 cases. Overall, 89 of 97 patients used a single injection of icatibant. No serious AEs or hospitaliza- tions were reported. Most patients (91.7%) found self-administration preferable to administration in the clinic. The median time to symptom relief (3.8 h) was comparable with results from controlled trials of icatibant.

Conclusions: With appropriate training, patients were successfully able to recog- nize HAE attacks and decide when to self-administer icatibant. This, coupled with the patient-reported high degree of satisfaction, convenience and ease of use supports the adoption of icatibant self-administration in clinical practice.